Meet the CEO of this Intrepid Spanish Biotech exploring Epigenetics

Located right here in Barcelona, Oryzon is one of the world’s few epigenetics biotechs. I sat down with CEO Carlos Buesa to talk about its approach.

Since its foundation in 2000, Oryzon has gone on to become the leader in epigenetic medicine and focuses on oncology. Most recently, the company announced the success of its lead candidate, ORY-1001, in Phase I for acute leukemia. The drug hit its primary and secondary endpoints, proving to be efficacious and tolerable in 41 patients.

Epigenetics has been a field of fascination for its links to cancer, but few intrepid biotechs have tried to develop a therapy out of it. Enthusiasm might have been renewed following a study in Nature Genetics that illustrated how epigenetic modifications allow tumor cell survival in healthy organs; but Oryzon has gotten a head start in the race!

Oryzon is leading the way with co-founder Carlos Buesa at the helm. He not only chairs the Board of Directors at his company but also serves on a number of others, including the Governing Board of ASEBIO, the Association of Spanish Biotechs.

You’d think with all of these obligations he wouldn’t have a spare moment — but I was lucky enough to catch him with a spare moment at lunch time; he even took the time to soothe my camera fright!

In the interview, I asked him more about the company’s R&D strategy and his view on the Spanish biotech ecosystem. Here’s what he had to say!

[poll id=1]

Support good journalism, subscribe to Labiotech Insider

Labiotech Insider

If you liked this post and want to read more good journalism, support us by joining Labiotech Insider. Our Insider membership gives you access to exclusive content and other advantages.

We use cookies to give you the best experience. If you click on accept, we also use tracking cookies for analytics and advertising purposes. Check our privacy policy for more details. By accepting, you support our independent media and its’ freely accessible content. You may withdraw your consent at any time.